The purpose of this study is to evaluate the pharmacokinetic (PK) of selexipag and ACT-333679
following single oral administration of the matrix tablet and the encapsulated pellets of
selexipag, each with 3 different release profiles, as compared to selexipag immediate release
(IR) tablets in healthy male participants.